Why the study?
Does carvedilol improve metabolic parameters compared to atenolol or doxazosin in patients with metabolic syndrome and stage 1 hypertension?
Population
77 patients ≥20 years of age with stage 1 hypertension and metabolic syndrome, mean age 52.3, 59 females.
Comparison
Carvedilol 12.5 mg/day orally for the first 2… vs Atenolol 50 mg/day orally or doxazosin 2 mg/day…
Design
RCT, randomly assigned
Follow-up
90 days
Authors
Loading...
Carvedilol may be preferred over atenolol or doxazosin for hypertension in metabolic syndrome; confirms metabolic advantages in this RCT.
Does carvedilol improve metabolic parameters compared to atenolol or doxazosin in patients with metabolic syndrome and stage 1 hypertension?
Carvedilol effectively reduces blood pressure without the adverse metabolic effects on HDL cholesterol and apolipoprotein A1 seen with atenolol or doxazosin in patients with metabolic syndrome.
Uzunlulu et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: